Migraine Clinical Trial
— MigreventionOfficial title:
Digital-technology Based Interventions on Treatment of Migraine.
NCT number | NCT05458817 |
Other study ID # | 20148 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2022 |
Est. completion date | May 31, 2025 |
The main aim of the research: To develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. Paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy).
Status | Recruiting |
Enrollment | 600 |
Est. completion date | May 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. diagnosed migraine, frequent episodic, headache days a month 8-14 days; 2. patient age 18-64 years; 3. very good command of the Estonian language both orally and in writing. Exclusion Criteria: 1. headaches lasting less than 8 days and more than 14 days per month; 2. all other primary and/or secondary diagnoses of headache; 3. under the age of 18 or over 64; 4. currently severe depression; 5. psychotic disorders; 6. pregnancy and lactation; 7. severe somatic disease; 8. severe organic mental disorders; 9. other chronic pain; 10. addictive disorders. |
Country | Name | City | State |
---|---|---|---|
Estonia | Tartu University Hospital | Tartu |
Lead Sponsor | Collaborator |
---|---|
Tartu University Hospital | University of Tartu |
Estonia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | headache frequency | headache diary: number of headache days per month | 3 months | |
Primary | headache frequency | headache diary: number of headache days per month | 6 months | |
Primary | headache frequency | headache diary: number of headache days per month | 9 months | |
Secondary | medication use | headache diary: number of headache days per month | 3 months | |
Secondary | medication use | headache diary: number of headache days per month | 6 months | |
Secondary | medication use | headache diary: number of headache days per month | 9 months | |
Secondary | The effect of headaches on everyday life | Headache Impact Test (HIT-6) | 3 months | |
Secondary | The effect of headaches on everyday life | Headache Impact Test (HIT-6) | 6 months | |
Secondary | The effect of headaches on everyday life | Headache Impact Test (HIT-6) | 9 months | |
Secondary | Pain acceptance Pain acceptance Pain acceptance | Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) | 3 months | |
Secondary | Pain acceptance Pain acceptance Pain acceptance | Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) | 6 months | |
Secondary | Pain acceptance Pain acceptance Pain acceptance | Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) | 9 months | |
Secondary | Pain-related anxiety | Pain Anxiety Symptoms Scale (PASS) | 3 months | |
Secondary | Pain-related anxiety | Pain Anxiety Symptoms Scale (PASS) | 6 months | |
Secondary | Pain-related anxiety | Pain Anxiety Symptoms Scale (PASS) | 9 months | |
Secondary | Health related quality of life | EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) | 3 months | |
Secondary | Health related quality of life | EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) | 6 months | |
Secondary | Health related quality of life | EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) | 9 months | |
Secondary | Patient satisfaction with treatment 1 | Headache Attributed Lost Time (HALT) | 3 months | |
Secondary | Patient satisfaction with treatment 2 | Headache Under-Response to Treatment (HURT) | 3 months | |
Secondary | Patient satisfaction with treatment 3 | Headache Attributed Lost Time (HALT) | 6 months | |
Secondary | Patient satisfaction with treatment 4 | Headache Under-Response to Treatment (HURT) | 6 months | |
Secondary | Patient satisfaction with treatment 5 | Headache Attributed Lost Time (HALT) | 9 months | |
Secondary | Patient satisfaction with treatment 6 | Headache Under-Response to Treatment (HURT) | 9 months | |
Secondary | Cost-effectiveness 1 | databases of the Estonian Health Insurance Fund, the Social Insurance Board and the Institute for Health Development (insurance costs per patient - sick leaves compensation) | 9 months | |
Secondary | Cost-effectiveness 2 | databases of the Estonian Health Insurance Fund, the Social Insurance Board and the Institute for Health Development (insurance costs per patient - medications reimbursement) | 9 months | |
Secondary | Patient's willingness to pay for headache treatment | Willingness to pay bidding game | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |